Expression of MMP-15 and MMP-24 in atherosclerotic and nonatherosclerotic coronary arteries

References

• Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409.
   PubMed Web of Science ®Google Scholar
• Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009;50:S364–S369.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol. 2009;31:23–33.
   Web of Science ®Google Scholar
• Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969–979.
   PubMed Web of Science ®Google Scholar
• Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17:4511–4520.
   PubMed Web of Science ®Google Scholar
• Salagianni M, Galani IE, Lundberg AM, et al. Toll-like receptor 7 protects from atherosclerosis by constraining “inflammatory” macrophage activation. Circulation. 2012;126:952–962.
   Web of Science ®Google Scholar
• Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953–957.
   PubMed Web of Science ®Google Scholar
• Stylianou IM, Bauer RC, Reilly MP, Rader DJ. Genetic basis of atherosclerosis: insights from mice and humans. Circ Res. 2012;110:337–355.
   PubMed Web of Science ®Google Scholar
• Woessner JF. Introduction to serial reviews: the extracellular matrix. FASEB J. 1993;7:735–736.
   Web of Science ®Google Scholar
• Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg. 2007;45:849–857.
   PubMed Web of Science ®Google Scholar
• Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1–31.
   PubMed Web of Science ®Google Scholar
• Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010;5:13–25.
   PubMed Web of Science ®Google Scholar
• Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990;87:5578–5582.
   PubMed Web of Science ®Google Scholar
• Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 2010;52:410–428.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503.
   PubMed Web of Science ®Google Scholar
• MonteroI I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006;47:1369–1378.
   Web of Science ®Google Scholar
• Schonbeck U, Mach F, Sukhova GK, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999;189:843–853.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1647–1653.
   Web of Science ®Google Scholar
• Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A. 1996;93:9748–9753.
   PubMed Web of Science ®Google Scholar
• Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res. 2008;121:535–542.
   PubMed Web of Science ®Google Scholar
• Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386:616–619.
   PubMed Web of Science ®Google Scholar
• Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis. 2008;13 Suppl 1:S1–S6.
   Google Scholar
• Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation. 1994;89:2462–2478.
   PubMed Web of Science ®Google Scholar
• Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20:1177–1178.
   PubMed Web of Science ®Google Scholar
• De B, Natchus MG, Cheng M, et al. The next generation of MMP inhibitors. Design and synthesis. Ann N Y Acad Sci. 1999;878:40–60.
   Web of Science ®Google Scholar
• Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr Med Chem. 2005;12:339–355.
   PubMed Web of Science ®Google Scholar
• Amalinei C, Caruntu ID, Giusca SE, Balan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 2010;51(2):215–228.
   PubMed Web of Science ®Google Scholar
• Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108–2114.
   PubMed Web of Science ®Google Scholar
• Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–1794.
   PubMed Web of Science ®Google Scholar
• Pearce E, Tregouet DA, Samnegård A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res. 2005;97:1070–1076.
   Web of Science ®Google Scholar
• Abilleira S, Bevan S, Markus HS. A role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet. 2006;43:897–901.
   PubMed Web of Science ®Google Scholar
• Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J. 2011;32:2314–2325.
   Web of Science ®Google Scholar
• Ray BK, Shakya A, Turk JR, Apte SS, Ray A. Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque: role of SAF-1 in the induction process. Circ Res. 2005;95:1082–0890.
   Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–673.
   PubMed Web of Science ®Google Scholar
• Mishra PK, Metreveli N, Tyagi SC. MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA. Cell Biochem Biophys. 2010;57:67–76.
   Web of Science ®Google Scholar
• Voloshenyuk TG, Gardner JD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol. 2010;299:683–893.
   PubMed Web of Science ®Google Scholar
• Kovatsi L, Batzios S, Nikolaou K, et al. Alterations in serum MMP and TIMP concentrations following chronic heroin abuse. Toxicol Mech Methods. 2013;23:377–781.
   PubMed Web of Science ®Google Scholar
• McGinn S, Poronnik P, Gallery ED, Pollock CA. The effects of high glucose and atorvastatin on endothelial cell matrix production. Diabet Med. 2004;21:1102–1107.
   Web of Science ®Google Scholar